Gland Pharma543245Board meeting scheduled
Board meeting on November 06, 2026 to consider unaudited results for the quarter and half year ended September 30, 2026
The Board of Directors will meet on Friday, November 06, 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
By ScoutQuest · · 2 min read
- Board Meeting Date
- Friday, November 06, 2026
- Investor/Analyst Call Time
- 18:30 Hrs (IST) on Friday, November 06, 2026
- Trading Window Reopens
- Monday, November 09, 2026
What was announced
- A meeting of the Board of Directors will be held on Friday, November 06, 2026.
- The board will, among other things, consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
- The intimation is dated October 21, 2026 and is signed by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer.
Earnings call
- An investor/analyst call will be held on Friday, November 06, 2026 at 18:30 Hrs (IST).
- Further details will be intimated to the stock exchanges and published on the company's website, www.glandpharma.com.
Trading window
- In continuation of an earlier intimation dated September 30, 2026, the trading window was closed from Thursday, October 01, 2026.
- It will reopen on Monday, November 09, 2026.
Why this matters to a retail investor
- This is a date announcement, not a results announcement. It tells you when the company's numbers for the September 2026 quarter and half year will be taken up by the board for approval and when they are expected to be made public.
- The earnings call on the same evening is the forum where management typically speaks about the quarter; the call details will be published separately on the company's website.
- The trading window reopening date matters if you are connected with the company or fall in the category of designated persons covered by the closure, as dealings in the company's shares are restricted while the window is shut.
What to watch for
- The board's approval and release of the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
- The investor/analyst call scheduled for November 06, 2026 at 18:30 Hrs (IST), details of which are to be published on the company's website.
- The reopening of the trading window on Monday, November 09, 2026.
Also from Gland Pharma
USFDA unannounced inspection at Dundigal formulation facility concludes with four Form 483 observations
23 Oct 2026
Gland Pharma to host Q2 FY27 earnings conference call on November 6, 2026 at 18:30 IST
21 Oct 2026
Board approves USD 21 million investment in US arm; 60% stake in Novelstar Pharma
1 Oct 2026
More numbers
- Earnings call time18:30 Hrs (IST)
Source: BSE · 21 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.